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Technetium-99m-labeled agents have advantages over thaI-
lium-20I in terms of photon statistics, cost and clinical
availability. They have been suggested as an alternative to
thallium for myocardial perfusion imaging. Teboroxime is
a new boronic acid adduct of technetium dioxime (BATO)
compound that demonstrates favorable characteristics in
preliminary studies. With use of a novel (seated) patient
positioning technique and a rapid dynamic acquisition
protocol, 30 patients underwent planar imaging with te-
boroxime while at rest and after maximal treadmill exer-
cise. Postexercise scans were completed in an average time
(mean ± SO) of 4.4 ± 1.6 min, with 4.8 ± 1.5 min for the
views at rest.
These results were compared with coronary arteriogra-
phy or thallium scintigraphy after treadmill exercise, or
Myocardial perfusion imaging at rest and after stress is an
extensively utilized technique for assessing the presence and
severity of coronary artery disease. Thallium-201 is the most
commonly used myocardial perfusion tracer; however, be-
cause it is a cyclotron product, its availability needs to be
prescheduled and can be limited, The photon energy (69 to
83 keY) detracts from optimal resolution and the prolonged
half-life of 73 h limits the dosage and restricts the ability to
perform sequential imaging (I). Therefore, this radiopharma-
ceutical compound is less than an ideal perfusion imaging
agent.
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both. Diagnostic agreement (abnormal versus normal) was
present in 28 of the 30 patients (p < 0.001). Regarding
physiologic assessment as compared with thallium scintig-
raphy, the finding of infarction and ischemia was concor-
dant in 89% and 86% of patients, respectively.
This report describes the initial use of teboroxime with a
rapid dynamic planar imaging technique, resulting in a
high correlation with exercise thallium scintigraphy. De-
layed postexercise images obtained 5 to 10 min after
exercise demonstrated rapid disappearance of exercise-
induced defects noted on the initial (0 to 5 min) postexercise
views. The rapid differential washout with teboroxime has
not been previously described and the possible clinical
significance is discussed.
(J Am Coil CardioI1990;16:855-6l)
Technetium-99m has photoperiod energy that is well
suited to gamma camera imaging. Furthermore, dosimetry
and availability enhance its potential clinical utility. Techne-
tium-99m teboroxime or SQ 30,217 (Cardiotec, Squibb Di-
agnostics), a newly engineered imaging agent, is a boronic
acid adduct of technetium dioxime (BATO) compound (2).
Initial experience reveals that teboroxime has a high degree
of myocardial extraction (2,3) and rapid blood pool clearance
(2,4) and correlates well with blood flow (2,4,5). Further-
more, the rapid clearance of teboroxime enables sequential
rest and exercise imaging to be done within a brief period
(6,7). The kinetics, transport properties and safety of this
compound appear promising for its use as a myocardial
perfusion agent and have prompted further investigation
(2-7).
Preliminary clinical studies (8,9) have demonstrated that
the results of imaging with teboroxime correlate well with
information obtained from thallium scintigraphy, coronary
arteriography, or both. Although there is good agreement
with thallium scintigraphy, imaging with teboroxime has
potential problems in relation to the inferior wall of the left
0735-1097190/$3.50
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ventricle because of extensive hepatic uptake and resultant
scatter of this agent (5-7).
Utilizing a novel patient positioning technique during
imaging and a rapid dynamic data acquisition protocol. we
compared planar imaging with teboroxime and information
obtained from thallium scintigraphy or coronary arteriogra-
phy in 30 patients. Images obtained at rest and after exercise
were compared and a description of the important temporal
relations of this unique radiopharmaceutical compound are
discussed.
Methods
Study patients. Thirty patients were randomly selected
from a group that had undergone cardiac catheterization or
exercise testing with thallium scintigraphy within the previ-
ous 3 months. All patients were >18 years of age and none
had had a myocardial infarction within the 3 months preced-
ing any imaging procedure. All women with child-bearing
potential were excluded. Informed consent was obtained
from each subject after review and approval by the institu-
tional review board.
Teboroxime preparation. Teboroxime was supplied as a
single vial kit in a lyophilized powder form. The vial was
reconstituted by adding ::s 100 mCi of technetium-99m in I ml
of 0.9% sodium chloride solution. The vial was placed in
100°C water bath for 15 min in a stationary upright position.
After the vial was allowed to cool to room temperature,
paper chromatography was performed to determine the
percent of free pertechnetate and reduced hydrolyzed tech-
netium. Two 1.3 x 11 cm strips of Whatman 31 ET paper
were spotted with 1 drop of the preparation. One strip was
developed in normal saline solution (percent free pertechne-
tate) and the other was developed in a I: I solution of normal
saline/acetone (percent reduced hydrolyzed technetium). As
a criterion for injection. the sum of the two percentages
could not exceed 10%. The reconstituted product was stored
in the original glass vial at room temperature and was
transferred to a syringe just before injection. Approximately
45 min was required for preparation of the compound and it
remained clinically usable for the next 6 h. Both rest and
exercise injections were made from contents of the same
vial; the dose of each was between 12 and 20 mCi.
Thallium scintigraphy. Maximal symptom-limited exer-
cise testing was performed with use of treadmill exercise and
the standard Bruce protocol. On attainment of maximal
effort, thallium-201 (2.2 to 2.8 mCi) was injected intrave-
nously and exercise continued for 30 to 60 s. Images were
acquired with use of a gamma camera in the 128 x 128 matrix
for 7 min in each of three views: 4SO left anterior oblique.
anterior and left lateral. Redistribution scans were obtained
in a similar manner 2.5 to 4 h later. Electrocardiographic
(ECG) monitoring of vital signs was done before, during and
after exercise.
Teboroxime scintigraphy. A similar exercise protocol
was performed as described for thallium scintigraphy; how-
ever, teboroxime (l2 to 20 mCi) was injected at maximal
exertion. The subjects were then expeditiously positioned
(seated) in front of the gamma camera (29 of 30 patients). An
upright position was selected for imaging to minimize the
interference by the hepatic uptake of tracer as previously
reported (6,7) and to allow rapid patient positioning. Data
collection was initiated within I min of the discontinuation of
exercise. With use of rapid dynamic acquisition with a frame
rate of 20 s/frame, data were acquired in a 64 x 64 matrix,
initially in the anterior view. Each view was continuously
monitored and 40 to 80 s (two to four frames) of data were
accumulated in the anterior position after blood pool clear-
ance. The subjects were then sequentially rotated in a chair
to the 4SO left anterior oblique and later the left lateral
position and data were acquired for 40 to 80 s/view. These
views were repeated in most subjects for analysis ofdelayed,
(5 to 10 min) postexercise images.
ImaRinR was repeated in the same fashion at rest after a
second injection of teboroxime. Postexercise imaging was
performed initially in the first 10 patients, with the rest scans
collected I to 1.5 h later. The next 20 patients were initially
studied at rest. followed by postexercise teboroxime imaging
performed I to 1.5 h after the rest scans. In five patients.
images were acquired immediately before the second te-
boroxime injection to confirm the absence of residual myo-
cardial activity.
Vital signs were obtained and ECG monitoring was
performed before. during and after exercise as well as
before. during and after injection ofteboroxime. Total image
collection times were recorded for teboroxime. In addition.
urine samples and blood samples (blood count. SMA-12
chemistry values) were collected before and after teborox-
ime administration. In all cases. no abnormal results were
noted.
Image processing and analysis. Teboroxime scans were
summated with the use of two to three frames for each view
(40 to 60 s). Images that showed significant amounts of blood
pool activity or motion artifact due to repositioning were
excluded.
The thallium and teboroxime images at rest and during
exercise were interpreted by at least two observers who were
blinded to patient data. Disagreements were resolved by
consensus after review of discordant interpretations. Each
scan was divided into nine segments and a score was
assigned corresponding to the number of abnormal segments
(0 to 9) as previously described (8). The quality of the
teboroxime scans was assessed subjectively as poor, fair or
good. Images that revealed abnormalities in the same seg-
ment on both rest and exercise scans were considered to
demonstrate nonviable infarcted myocardium. A segment
that demonstrated an abnormality on the postexercise scan
but not on the corresponding rest study was defined as
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Table 1. Comparison of Exercise Testing in 28 Patients
less time and had a lower heart rate and rate-pressure
product during the teboroxime exercise test than during
thallium imaging. There were five patients with ischemic
ECG changes during exercise thallium scintigraphy but not
during the teboroxime stress test. A lower maximal heart
rate and rate-pressure product were noted in four of the five
patients during the teboroxime test. There was no alteration
in cardiac medications between the studies in any of the
aforementioned patients. All remaining patients who had
both teboroxime and thallium exercise scintigraphic imaging
demonstrated concordant ECG changes or symptoms.
Teboroxime scintigraphy. The dose of technetium-99m
was 15.3 ± 1.8 mCi for images at rest and 16.7 ± 1.6 mCi for
postexercise scans. The mean time between the rest and
exercise images was 97 ± 33 min. Imaging was completed in
an average of 4.8 ± 1.5 min for the rest images and 4.4 ± 1.6
min for postexercise scans. The dynamic images were re-
viewed to estimate the time required from the initiation of
data acquisition until the completion of imaging in the three
views. By combining the time required for clearance of the
blood pool (40 to 60 s), the one frame (20 s) for repositioning
between each view and two to three frames of data acquisi-
tion for each projection, we were able to estimate the time
required for completion of each study. With these estima-
tions, 3.0 ± 0.4 and 3.2 ± 0.8 min were required to complete
imaging at rest and after exercise, respectively.
The quality of the tehoroxime images was rated as
excellent or satisfactory in 29 of 30 scans at rest and 26 of 30
scans after exercise. Examination for residual myocardial
activity was performed in five patients approximately 96 ±
18 min after imaging at rest. Four of these patients had
essentially no detectable myocardial activity and one patient
had minimal residual myocardial counts (liver activity much
greater than myocardial activity).
Comparison of teboroxime with thallium or angiography.
With teboroxime scintigraphy, 10 patients were noted to
have normal scans; of these, 9 had thallium scans performed,
8 of which were interpreted as normal (Fig. I). The discor-
dant thallium study demonstrated a transient defect in one
segment. However, this patient underwent cardiac catheter-
ization that failed to demonstrate any significant coronary
stenosis. a finding consistent with the teboroxime scan.
showing transient myocardial hypoperfusion consistent with
ischemia.
Teboroxime scintigrams were compared with thallium
studies for determination of normal or abnormal scans. The
diagnosis of ischemia or presence of infarction was also
correlated between these two imaging techniques. Further-
more, the rest and exercise images immediately after the
injection of teboroxime were compared with repeat scans
obtained after the collection of the first set of postexercise
views. These early repeat scans are referred to as "delayed"
teboroxime images. The quality of the delayed scans was
also subjectively assessed. Finally, an estimate was made of
the time required for the performance of each teboroxime
scan based on the time required for blood pool clearance,
data acquisition and repositioning of the patient.
Statistics. Paired t test analysis was performed to com-
pare the exercise variables of each scintigraphic study.
Fisher's exact test was utilized to determine the significance
of the correlation of the teboroxime and thallium scans with
regard to the presence or absence of an abnormal scan,
transient myocardial ischemia or prior '1yocardial infarc-
tion.
Results
Patient characteristics. Thirty subjects (9 women and 21
men, mean age ± SD 55 ± 13 years) were enrolled in this
phase III trial of teboroxime. Prior myocardial infarction
was present in 19 patients. Acalcium channel antagonist was
being taken by 15 subjects and beta-adrenergic blocking
medication by 10. No attempt to alter medications was made
before either exercise perfusion study.
Coronary arteriography and contrast ventriculography
were performed in nine patients, with one patient demon-
strating three vessel coronary artery disease, three having
two vessel disease, two with one vessel disease and three
without significant obstructive lesions in the coronary arter-
Ies.
Exercise testing. All patients underwent exercise testing
with teboroxime imaging and 28 patients also performed
treadmill exercise with thallium scintigraphy. The level of
exercise achieved, hemodynamic response and the develop-
ment of ischemic ECG changes or chest pain are summa-
rized in Table I. Paired analysis revealed a trend for the total
exercise time and percent of maximal predicted heart rate to
be higher in the thallium group (0.06 < P < 0.08). The other
exercise-related variables (heart rate-blood pressure prod-
uct, chest pain and ST segment depression on the ECG)
were not significantly different.
Several patients had discordant symptoms or ECG ab-
normalities between the thallium and tehoroxime exercise
studies. Anginal chest pain was experienced by two patients
during the thallium exercise test but not before the adminis-
tration of teboroxime. Both of these patients exercised for
Exercise duration (min)
Maximal predicted heart rate (91:)
Rate-pressure product
(mm Hg x beats/min)
Patients with chest pain (no.1
Patients with electrocardiographic
changes (no.)
*0.06 < P < 0.08.
Thallium
8.3 :±: 2.6*
82 :±: 12*
24.200 :±: 5.900
12
Teboroxime
7.6 :±: 3.1 *
81 :±: 13*
23.800 :±: 5.100
8
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Figure 1. Comparison of thallium (A) and teboroxime (8) scintigra-
phy. This patient had normal images in both studies. Note the
presence of significant hepatic activity in the teboroxime scan. ANT
== anterior; LAO == 45° left anterior oblique; LAT == left lateral.
Additionally. there was one thallium scan interpreted as
normal in a patient who had an abnormal teboroxime scin-
tigram with a persistent defect in one segment.
Overall, there was excellent correlation between teborox-
ime imaging and thallium scintigraphy or cardiac catheter-
ization regarding the diagnosis of normal or abnormal myo-
cardial perfusion. With regard to differentiating normal from
abnormal scans, 28 of 30 patients demonstrated agreement
when teboroxime was compared with thallium or catheter-
ization (p < 0.(01). yielding an overall predictive accuracy
for teboroxime scintigraphy of 93%. A comparison of te-
beroxime imaging with coronary angiography revealed con-
cordance for coronary artery disease in all nine patients.
Table 2 summarizes the comparison of findings after
thallium and teboroxime administration in the study group.
Analysis for the presence or absence of a defect consistent
with a myocardial scar revealed agreement between the
imaging techniques in 25 of 28 patients (p < 0.0001). Addi-
tionally, transient abnormalities (defect present on postex-
Table 2. Diagnostic Correlation of 30 Patients Undergoing
Teboroxime Scintigraphy
Figure 2. Comparison of thallium (A) and teboroxime (8) scintigra-
phy. This patient demonstrated a defect on both the rest (redistri-
bution) and immediate postexercise studies for both thallium and
teboroxime. Similarity in the scans is apparent, but apical defects
are less apparent on rest teboroxime images compared with the
thallium images. Abbreviations as in Figure I.
ercise studies that was not present on rest images; that is,
thallium redistribution) were also concordant in 24 of 28
studies (p < 0.0005) (Fig. 2).
There were 20 teboroxime studies that were abnormal,
with the presence of persistent or transient defects, or both.
Overall. close correlation between the diagnostic techniques
existed in 15 (75%) of the abnormal studies. However,
several teboroxime scintigrams revealed more segments
showing ischemia than the corresponding thallium study.
Five of the 20 abnormal studies had significant differences
regarding the presence or absence of myocardial ischemia or
myocardial scar (Table 3). In four of the five studies, the
teboroxime scan demonstrated more ischemia than the thal-
lium scan. In fact. three studies had only a persistent defect
noted on thallium scintigraphy. with no evidence for myo-
cardial ischemia. The regions of scar on the thallium study
were similar to the abnormal regions on the teboroxime
scans. An additional discordant study revealed a persistent
Table 3. Discordant Segmental Imaging Results in Five Patients
Abnormal Versus Norma" Ischemia Infarction
Comparison With
Thallium
No.
Concordance (no.)
Concordance (%)
p value (chi-square)
Diagnosis
30
28
93
<0.0001
28
24
86
<0.0005
28
25
89
<0.0001
Patient
Thallium'
No. Ischemia Infarction
4 0 6
6 0 3
8 0 2
13 0 0
20 ,
Teboroxime'
Ischemia Infarction
2 4
3 2
2 0
0 I
2 0
'Teboroxime compared with thallium or coronary angiography. 'Number of abnormal segments (0 to 9).
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Figure 3. Delayed (5 to 10 min) postexercise teboroxime image
analysis in 26 patients. See text for details.
~?p 'Delayed' Scans
[EJ Abnormal Early Scan Available
No Difference ~ ""~ Difference Present
Early vs Delay ~ L::u Early vs Delay
IMMED "DELAY" REST
POST 5 min
STRESS POST
STRESS
Figure 4. Summated teboroxime images (40 s) in the anterior (ANT)
view. showing the immediate OMMED) (0 to 5 min) and delayed
("delay") post-stress scans and the scan at rest (separate injection).
The defect noted on the initial image after exercise is not present on
the delayed image. suggesting rapid differential washout. The de-
layed image resembles the rest study.
Discussion
Teboroxime versus thallium imaging. The present study
demonstrates the diagnostic utility of teboroxime, a new
myocardial perfusion agent, when used with a rapid planar
imaging protocol. Although some diagnostic differences ex-
ist between thallium and teboroxime imaging, there is close
correlation between these techniques. This is true not only
for differentiating abnormal from normal scans, but also for
the detection of myocardial ischemia and the presence of
preexisting myocardial infarction. Thus, this is the first
report of a rapid planar imaging technique that yields a high
correlation with standard exercise thallium imaging results.
In addition, this is the initial report of the presence of early
differential washout of teboroxime after postexercise injec-
tion.
Critique of methods. The methods in the present study
differed from previous experience in several ways. First,
previous clinical work with teboroxime (7) has utilized a
bicycle exercise protocol for teboroxime and treadmill exer-
cise for thallium. Only one study (6) used treadmill exercise
testing for teboroxime scintigraphy and then compared the
results only with coronary angiography. Therefore, this
report represents the first direct comparison of similar exer-
cise protocols for both thallium and teboroxime imaging.
The major technical differences in our study were related
to imaRe acquisition. Although different protocols have been
utilized previously, all required a minimum of 14 min after
blood pool clearance (6,7), which is in sharp contrast to the
<5 min required in our study. Rapid repositioning was
possible, with the patients being swiveled in a chair while
seated. The seated position also theoretically allowed for
inferior displacement of the liver, thereby reducing the
potential for hepatic interference with the inferior wall,
which has previously been described as a problem (6,7).
Because our image acquisition time was very brief, all
patients were able to tolerate this position without difficulties
or significant motion. Since residual myocardial activity was
essentially absent at the time of the second study, it appears
Ischemia Present
Rest/Exercise
No Ischemia
Rest/Exercise
defect in one segment consistent with an apical scar on
teboroxime imaging that was not apparent with thallium
scanning. The level of exertion. as assessed by total exercise
time. percent of maximal predicted heart rate and rate-
pressure product, were not significantly different between
these discordant thallium and teboroxime exercise studies.
With respect to the cumulative totals of abnormal segments,
more transient (ischemic) abnormalities were present with
teboroxime than with thallium (44 versus 30).
In a subset analysis of patients without prior myocardial
infarction, 10 (91%) of II studies had diagnostic concor-
dance (abnormal versus normal). with the outlying study
revealing a small persistent apical defect after teboroxime
injection that was interpreted as normal on thallium scintig-
raphy. There was also agreement for the presence of ische-
mia or infarction. or both, in these 10 studies, with the
exception of I study that showed a persistent and transient
perfusion abnormality with thallium imaging, but only a
transient defect with teboroxime imaging.
Delayed postexercise teboroxime scintigraphy. Repeat im-
ages were obtained in 26 of the 30 patients after the initial
postexercise teboroxime scans (Fig. 3). There were 15
studies that had abnormal images on the initial scintigrams
that could permit comparison with delayed images for pos-
sible rapid changes in tracer distribution. Clearly, an initial
normal image could not demonstrate a transient-type defect.
One repeat study was technically inadequate to allow com-
parison. The delay between the initial and the delayed
postexercise views was 4.2 ± 1.7 min. Of these 14 abnormal
early studies, 9 demonstrated differences in the delayed
postexercise views compared with those obtained within the
first 5 min after teboroxime injection (Fig. 4). All of these
delayed images were identical to images on the rest scans. In
five patients there were no apparent differences between the
early and delayed stress scans. Three of these scans dem-
onstrated only a persistent defect and thus would not be
expected to reveal changes from the early to delayed post-
exercise images. Only two studies revealed a transient defect
that failed to have noticeable changes between the two
postexercise scans. Thus, 9 of II patients with ischemic
defects demonstrated this rapid redistributionlike phenome-
non within several minutes.
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that the entire study may be completed within 1.5 to 2h after
the conclusion of exercise.
Correlation of teboroxime with thallium imaging. The
correlation between the thallium and teboroxime scans was
very good and was consistent with the high degree of
agreement previously noted between these two techniques
(6,7). The teboroxime scans, however, demonstrated more
potential ischemic segments than did the corresponding
thallium scintigrams.
Delayed postexercise teboroxime images. The finding of
rapid changes after postexercise teboroxime injection has
not been previously described. The majority of images (82%)
acquired approximately 5 to 10 min after the teboroxime
injection demonstrated the rapid disappearance of defects
present on the initial (0 to 5 min) postexercise images. This
phenomenon is similar to the description of thallium redis-
tribution where initial defects disappear on the 2 to 4 h
delayed scans (9-12).
The mechanism of redistribution after thallium injection
may involve the continued extraction of thallium into the
ischemic segment from the blood pool (9.10) as well as
differential washout from regions of disparate blood flow
(11-\3). The latter mechanism reflects the more rapid net
clearance of thallium from normally perfused myocardium
that from an area with reduced flow. Even with thallium.
several investigators (9.10) caution against substantial delays
(> I h) after injection of the cation because this may result in
a failure to detect ischemic regions as a result of relatively
rapid redistribution.
A disparity in net myocardial clearance from ischemic
compared with normal areas of myocardium may account
for the rapid resolution of ischemic-type defects noted on the
delayed postexercise teboroxime scans in this study. Further
research on the mechanism of this phenomenon is required.
It is apparent, however. that interpretation of teboroxime
scans after 5 min may reflect this differential washout and
false negative scans for ischemia may result. The slightly
diminished diagnostic accuracy of previous studies (6.7) may
have been influenced by a more prolonged (~14 min) acqui-
sition of data and consequently diminished imaging statistics
for these final views. Improved diagnostic accuracy has been
noted with the use of single photon emission computed
tomographic imaging compared with the planar method
(6,7); however, given the finding of rapid differential wash-
out of teboroxime, caution should be advised with this
imaging technique, when it involves >5 to 10 min of acqui-
sition time.
Clinical significance and limitations. The present study
has several limitations. Because the first 10 patients had the
exercise teboroxime studies performed first and the remain-
ing 20 had rest scans collected before exercise studies, the
protocol was not constant. However. there was no signifi-
cant difference in teboroxime imaging results, except that
the quality of the rest study appeared slightly better when it
preceded exercise. Because the imaging characteristics and
time course were not clearly defined at the onset of the
study. data acquisition was more prolonged than necessary.
It is now apparent that valid scans can be performed in 3 to
3.5 min and more rapid acquisition of data may be utilized in
the future. The lack of quantitative analysis to characterize
myocardial clearance of teboroxime was an additional limi-
tation. Although a rapid decrease in myocardial counts was
noted in some patients (approximately 5%/min), not all
studies were quantitated. Segmental quantitation also was
not performed and. therefore. assessment of differential
myocardial clearance was not critically analyzed.
Hepatic uptake of teboroxime is a potential source of
imaRe misinterpretation. especially in the left lateral projec-
tion (6,7). Therefore, we used upright positioning of the
patients to allow a downward displacement of the liver.
Although occasional overlap of the myocardium and liver
was present. this did not appear to affect the results of
teboroxime scintigraphy. Although tomographic imaging
may help alleviate this potential pitfall, the rapid clearance
kinetics of teboroxime may limit the application of a single-
headed single photon emission computed tomographic sys-
tem.
Coronary angioRl'aphy. the accepted standard for diag-
nosis of coronary artery disease. was performed in relatively
few patients. However. other studies (6,7) have confirmed
the diagnostic correlation of teboroxime and cardiac cathe-
terization. Our study was more concerned with the compar-
ison with thallium scintigraphy because both teboroxime and
thallium provide physiologic information regarding the pres-
ence or absence of ischemia and myocardial infarction.
In addition. the observed increased incidence of transient
(stress-induced) perfusion defects by teboroxime compared
with thallium may relate to the imaging techniques utilized.
A separate rest and stress thallium study may detect up to
20% more transient defects compared with stress and 4 h
redistribution scans (13). It is also possible that 24 h delayed
thallium scans or thallium reinjection scans would detect
more exercise-induced perfusion defects than the standard
3 to 4 h redistribution images (14). The present study
suggests that the rapid imaging protocol involving separate
rest and stress injections ofteboroxime results in a faster and
potentially more sensitive technique to detect stress-induced
hypoperfusion than standard thallium (exercise and 3 to 4 h
redistribution) imaging. Further investigations of the dif-
ferent thallium and teboroxime protocols are clearly war-
ranted before the superiority of one perfusion imaging
method over another can be determined.
Conclusions. Teboroxime demonstrates excellent diag-
nostic correlation with thallium in the diagnosis of abnormal
versus normal myocardial perfusion scans as well as close
agreement in the detection of myocardial ischemia or infarc-
tion. or both. The myocardial kinetics of this new techne-
tium perfusion agent allow both extremely rapid data acqui-
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sition and completion of sequential stress and rest scanning
within 1.5 to 2 h. There appears to be evidence for rapid
differential washout of teboroxime and a rapid disappear-
ance of exercise-induced defects is often noted. Although
the initial evidence suggests that these effects may resemble
the phenomenon of thallium redistribution. additional re-
search is needed. However. this study does suggest the
intriguing possibility that performing an exercise study with
teboroxime could permit detection of ischemic heart disease
within 10 min after tracer injection.
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